A new study shows that a radiotracer can effectively image fibroblast activation after a heart attack. This could lead to improved outcomes for heart attack patients.

MDDI Staff

January 6, 2020

2 Min Read
Using Imaging for Early Intervention After a Heart Attack
Image by Geralt on Pixabay

Researchers from Klinikum rechts der Isar der Technical University of Munich, Germany have found that a new radiotracer can effectively image fibroblast activation after a heart attack and identify a window of time during which cardiac fibrosis can be prevented and the disease course altered.

The team used a novel 68Ga-labeled fibroblast activation protein (FAP) inhibitor and research regarding the technique was published in the December issue of The Journal of Nuclear Medicine

The preclinical study included 20 rats subjected to myocardial infarction by permanent ligation of the left anterior descending coronary artery, as well as four sham-operated rats that underwent the same procedure except for the ligation. In vivo imaging with 68Ga-FAPI-04 PET was performed at one, three, six, 14, 23, and 30 days after the myocardial infarction and with 18F-FDG three days after myocardial infarction. Dynamic 68Ga-FAPI-04 PET and blocking studies were performed on the myocardial infarction rats on day seven. Ex vivo imaging, autoradiography, histologic studies and immunofluorescence staining were also conducted to validate the results of in vivo imaging.

Researchers found that uptake of 68Ga-FAPI-04 PET peaked six days after ligation and decreased rapidly to the background level by two weeks after infarction. Uptake accumulated mainly at the border zone of the infarcted myocardium, with high contrast and minimal uptake in normal myocardium. Minimal uptake was noted in rats that received a blocking dose of non-labeled FAPI-04. The exact location of the 68Ga-FAPI-04 uptake was confirmed by ex vivo imaging, as well as autoradiography and histologic findings.

In a release, Zohreh Varasteh, PhD, a research fellow at Klinikum rechts der Isar der Technical University of Munich, Germany, said "while preclinical development of potential anti-fibrotic approaches is far advanced, there has been little clinical validation due to the lack of sensitive and specific imaging technologies for assessing cardiac fibrosis progression or regression. In this regard, 68Ga-FAPI-04 PET has emerged as an important tool for the detection of fibrotic processes in the efforts to improve heart failure therapy.”

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like